Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088605 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
A Phase 2 study, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT03088605: Completed Phase 2 study, sponsored by ORA.
NCT03088605 is a Phase 2 study that has completed, run by ORA. The registered enrollment target is 69 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03088605, a Phase 2 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo. The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Primary Outcome
Visual Acuity will be measured using the EDTRS chart to assess changes from baseline
Interventions
- DRUG TOP1630 Ophthalmic Solution
- DRUG Placebo to TOP1630 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 2 |
What the finished NCT03088605 record still lists
NCT03088605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which TOP1630 Ophthalmic Solution is the first listed.
NCT03088605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03088605 about?
NCT03088605 is a clinical study titled "Safety and Efficacy of TOP1630 for Dry Eye Syndrome". In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo. The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of ...
What is the current status of trial NCT03088605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2017-02-20. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT03088605?
The interventions under investigation include: TOP1630 Ophthalmic Solution (DRUG), Placebo to TOP1630 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03088605?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03088605's enrollment target sits among peer trials
69 965th of 2000 higher than 1,034 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI